Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
armored B7H3-HypoxiCAR T cells
- Development stage
- Preclinical
- Lead developer
- King's College London
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, Cytokines & Interferons → Recombinant Proteins and Enzymes
- Administration
- Intravenous
01
Overview
Armored B7H3-HypoxiCAR T cells are an experimental autologous CAR T-cell therapy designed to treat solid tumors, specifically neuroblastoma. This platform utilizes a dual oxygen-sensing 'HypoxiCAR' switch that restricts the expression of both the B7-H3-targeting chimeric antigen receptor and the 'armoring' payloads (pro-inflammatory cytokines IL-12 and IL-23) to the hypoxic tumor microenvironment (TME). By limiting expression to hypoxic regions, the therapy aims to enhance anti-tumor efficacy through cytokine-mediated immune modulation while minimizing systemic 'on-target, off-tumor' toxicities in healthy, normoxic tissues. Preclinical studies demonstrate superior anti-tumor activity and a favorable safety profile compared to unarmored versions, with the ability to reprogram the TME and boost effector functions selectively within the tumor.
- Other names
- B7H3-HypoxiCAR T cellsB-7H3-HypoxiCAR T cellsB 7H3-HypoxiCAR T cellsIL12/IL23 armored B7H3-HypoxiCAR T cellshypoxia-inducible armored CAR T cells
02
Targets
IL23R (Interleukin-23 Receptor)B7-H3IL-12R (Interleukin-12 receptor)
Beyond the preview
Go deeper on armored B7H3-HypoxiCAR T cells.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on armored B7H3-HypoxiCAR T cells.